Chemoprevention strategies in the prostate: an overview.

Chemoprevention is the administration of agents (drugs, biologics, and nutrients) to prevent induction, inhibit, or delay the progression of cancers. Prostate cancer is an important target for chemoprevention because of its long latency and high prevalence. The development of rational chemopreventive strategies requires knowledge of the mechanisms of prostate carcinogenesis and identification of agents that interfere with these mechanisms. Because of the long time period for prostate carcinogenesis and the large size of the cohort required for an evaluable study, identification and characterization of early intermediate biomarkers and their validation as surrogate endpoints for cancer incidence are essential for chemopreventive agent development. Finally, suitable populations with appropriate risk factors, including the presence of premalignant lesions and genetic predispositions, need to be well characterized for future chemopreventive interventions.

[1]  N. Fleshner,et al.  Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case control study , 2000, Prostate Cancer and Prostatic Diseases.

[2]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[3]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[4]  V. Steele,et al.  Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. , 2000, The Journal of nutrition.

[5]  E. Hawk,et al.  Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  M. Karas,et al.  Lycopene Interferes With Cell Cycle Progression and Insulin-Like Growth Factor I Signaling in Mammary Cancer Cells , 2000, Nutrition and cancer.

[7]  D. Bostwick,et al.  Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.

[8]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[9]  Randall Harris,et al.  Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. , 2000, Oncology reports.

[10]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[11]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[12]  C. Young,et al.  A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. , 1999, Endocrinology.

[13]  D. Bostwick.  Prostatic intraepithelial neoplasia is a risk factor for cancer. , 1999, Seminars in urologic oncology.

[14]  V. Steele,et al.  Progress in Cancer Chemoprevention , 1999, Annals of the New York Academy of Sciences.

[15]  G. Piazza,et al.  Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. , 1999, Biochemical pharmacology.

[16]  A Heerschap,et al.  Fast dynamic gadolinium‐enhanced MR imaging of urinary bladder and prostate cancer , 1999, Journal of magnetic resonance imaging : JMRI.

[17]  G. Blackburn,et al.  Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. , 1999, The Journal of nutrition.

[18]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase‐2 inhibitor, and indomethacin against ultraviolet light–induced skin carcinogenesis , 1999, Molecular carcinogenesis.

[19]  M. Sporn.  New Agents for Chemoprevention of Prostate Cancer , 1999, European Urology.

[20]  D. Bostwick,et al.  Reversibility of Prostatic Intraepithelial Neoplasia: Implications for Chemoprevention , 1999, European Urology.

[21]  P. Feigl,et al.  Prostate Cancer Prevention Trial (PCPT) Update , 1999, European Urology.

[22]  V. Steele,et al.  Chemoprevention of Prostate Cancer: Concepts and Strategies , 1999, European Urology.

[23]  C. Myers,et al.  Lipoxygenase Inhibition in Prostate Cancer , 1999, European Urology.

[24]  S. Gupta,et al.  Prostate cancer chemoprevention by green tea. , 1999, Seminars in urologic oncology.

[25]  C C Sigman,et al.  Lipoxygenase inhibitors as potential cancer chemopreventives. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  R. Mohan,et al.  Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. , 1999, Cancer research.

[27]  D. Tindall,et al.  Defeating prostate cancer: Crucial directions for research—excerpt from the report of the Prostate Cancer Progress Review Group , 1999, The Prostate.

[28]  V. Steele,et al.  Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. , 1999, Cancer research.

[29]  E. Lander,et al.  Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility , 1998, European Urology.

[30]  R. Elashoff,et al.  Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. , 1999, Nutrition and cancer.

[31]  E. Okajima,et al.  Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. , 1998, Japanese journal of cancer research : Gann.

[32]  T. Inakuma,et al.  Prevention of N‐Methylnitrosourea‐induced Colon Carcinogenesis in F344 Rats by Lycopene and Tomato Juice Rich in Lycopene , 1998, Japanese journal of cancer research : Gann.

[33]  C. Turner,et al.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  C. Lamartiniere,et al.  Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate , 1998, The Prostate.

[35]  A. Norrish,et al.  Non‐steroidal anti‐inflammatory drugs and prostate cancer progression , 1998, International journal of cancer.

[36]  M. Pike,et al.  The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. , 1998, British Journal of Cancer.

[37]  F. Khachik,et al.  Lycopene Uptake and Tissue Disposition in Male and Female Rats 1 , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  B. Turnbull,et al.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. , 1998, British journal of urology.

[39]  S B Malkowicz,et al.  Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. , 1998, Urology.

[40]  S. Ripatti,et al.  Prostate Cancer and Supplementation With -Tocopherol and -Carotene: Incidence and Mortality in a Controlled Trial , 1998 .

[41]  A. Azzi,et al.  Lycopene in Association with a-Tocopherol Inhibits at Physiological Concentrations Proliferation of Prostate Carcinoma Cells , 1998 .

[42]  F. Collins,et al.  Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. , 1998, JAMA.

[43]  D. Bostwick,et al.  Androgen deprivation as a strategy for prostate cancer chemoprevention. , 1997, Journal of the National Cancer Institute.

[44]  V. Steele,et al.  Progress in clinical chemoprevention. , 1997, Seminars in oncology.

[45]  J. Levy,et al.  Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors. , 1997, Cancer detection and prevention.

[46]  K. Seibert,et al.  Advances in Brief Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis ' , 2006 .

[47]  D. Bostwick,et al.  cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[48]  V. Steele,et al.  Strategies for identification and clinical evaluation of promising chemopreventive agents. , 1996, Oncology.

[49]  V. Steele,et al.  Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. , 1996, Carcinogenesis.

[50]  G. Coetzee,et al.  Genetic susceptibility to cancer from exogenous and endogenous exposures , 1996, Journal of cellular biochemistry. Supplement.

[51]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[52]  M. Anver,et al.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. , 1995, Cancer research.

[53]  D. Bostwick,et al.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. , 1995, Cancer research.

[54]  V. Steele,et al.  Chemoprevention of Colon Carcinogenesis by Sulindac , a Nonsteroidal Anti-inflammatory Agent 1 , 2022 .

[55]  J. Harris,et al.  The selective 5-lipoxygenase inhibitor A63162 reduces PC3 proliferation and initiates morphologic changes consistent with secretion. , 1994, Anticancer research.

[56]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Bostwick.  Target populations and strategies for chemoprevention trials of prostate cancer. , 1994, Journal of cellular biochemistry. Supplement.

[58]  D. Bostwick,et al.  The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. , 1994, Journal of cellular biochemistry. Supplement.

[59]  M. Nevalainen,et al.  Hormone regulation of human prostate in organ culture. , 1993, Cancer research.

[60]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[61]  E. Vaughan,et al.  The Clinical Effects of a 5α-Reductase Inhibitor, Finasteride, on Benign Prostatic Hyperplasia , 1992 .

[62]  V. Steele,et al.  Introductory remarks: Development of chemopreventive agents for prostate cancer , 1992, Journal of cellular biochemistry. Supplement.

[63]  D. Kadmon,et al.  Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO) , 1992, Journal of cellular biochemistry. Supplement.

[64]  M. Sporn,et al.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. , 1991, Cancer research.

[65]  P. Di Mascio,et al.  Lycopene as the most efficient biological carotenoid singlet oxygen quencher. , 1989, Archives of biochemistry and biophysics.

[66]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[67]  Allan H. Smith,et al.  Subversion of immune system by tumor cells and role of prostaglandins. , 1975, Proceedings of the National Academy of Sciences of the United States of America.